시장보고서

상품코드

1756395

세계의 유전자 편집 치료제 시장 : 기술별, 개발 단계별, 치료 종류별, 적응증별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

Gene Editing Therapeutics Market, By Technology, By Development Stage, By Therapy Type, By Disease Indication, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 05월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 260 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

유전자 편집 치료제 시장 규모는 2024년 1,113만 달러로 평가되며 2025년부터 2032년까지 CAGR 147.20%로 확대될 전망입니다.

유전자 편집 치료제 시장 역학

획기적인 임상 승인과 정밀한 도구로 치료제 채택 촉진

Vertex Pharmaceuticals와 CRISPR Therapeutics가 제휴하여 개발한 겸상 적혈구증에 대한 첫 번째 CRISPR 기반 치료제가 미국 FDA의 승인을 받음으로써 전 세계적으로 유전자 편집 치료제의 채택이 가속화되고 있습니다. 2023년 승인은 유전자 편집의 임상 적용을 향한 역사적인 전환점이 되었습니다. 동시에 미국 국립보건원(NIH)은 정밀 유전체 공학 연구에 대한 자금 지원을 늘리고, 표적 외 영향이 적은 돌연변이를 교정하기 위한 염기교정 및 프라임 편집과 같은 도구를 장려하고 있습니다. 영국에서는 의약품 및 헬스케어 제품 규제청(MHRA)이 유전자 편집 치료의 조기 심사 경로를 개시하여 첨단 치료법을 환자에게 더 빨리 제공하는 것을 목표로 하고 있습니다. 이러한 발전은 유전자 편집의 안전하고 효율적이며 확장 가능한 치료적 응용에 대한 전 세계적인 관심의 증가를 반영하고 있으며, 유전성 질환, 암 및 복잡한 질환의 치료를 변화시킬 수 있는 잠재력을 강화하고 있습니다.

유전자 편집 치료제 시장 : 주요 인사이트

당사의 연구 분석가들이 공유한 분석에 따르면, 세계 시장은 예측 기간(2025-2032년) 동안 약 147.20%의 CAGR로 매년 성장할 것으로 예상됩니다.

기술별로는 CRISPR이 2024년 가장 큰 시장 점유율을 보일 것으로 예측됐습니다.

개발 단계별로는 2024년 전임상이 1위를 차지했습니다.

치료 유형별로는 체외 유전자 편집이 2024년 주요 치료 유형으로 꼽혔습니다.

적응증별로는 유전자 질환이 2024년 주요 질환으로 나타났습니다.

최종사용자별로는 바이오 제약회사가 2024년 주요 최종사용자로 나타났습니다.

지역별로는 북미가 2024년 매출을 주도하고 있습니다.

유전자 편집 치료제 시장 : 세분화 분석

세계 유전자 편집 치료제 시장은 기술, 개발 단계, 치료 유형, 제왕성, 최종사용자, 지역에 따라 세분화됩니다.

시장은 기술에 따라 CRISPR, ZFN, TALEN, 염기교정, RNA 편집, CRISPR이 간편성과 고효율로 선두를 달리고 있고, ZFN은 특이성을 제공하지만 복잡한 설계가 필요하며, TALEN은 유전자 녹아웃 연구에서 표적 정확도로 평가되고 있습니다. 유전자 녹아웃 연구에서의 표적 정확도로 평가되고 있으며, 염기교정은 단일 염기 변경을 가능하게 하고, RNA 편집은 DNA를 변경하지 않고 일시적인 변형이 가능합니다.

시장은 개발 단계에 따라 5가지 카테고리로 나뉩니다. 전임상, 1상, 2상, 3상, 승인 후입니다. 전임상 단계는 많은 수의 후보물질이 조사 중이고, 임상 1상은 안전성 프로파일링에 초점을 맞추고, 임상 2상은 치료 효과를 조사하며, 임상 3상은 전체 집단에 대한 대규모 검증을 포함합니다.

유전자 편집 치료제 시장 : 지역별 분석

유전자 편집 치료제 시장은 첨단 생명공학 인프라, 광범위한 임상 연구 활동, FDA와 같은 기관의 지원적인 규제 프레임워크로 인해 북미를 필두로 강력한 지역적 역동성을 보이고 있습니다. 미국은 CRISPR 기반 치료법의 승인 및 임상시험에서 선두를 달리고 있으며, 공공 및 민간으로부터의 막대한 자금 지원으로 강화되고 있습니다. 영국, 독일, 스위스 등의 국가들이 정밀의료에 적극적으로 투자하고 있으며, EMA와 같은 규제 기관도 혁신적인 유전자 치료법을 점점 더 많이 수용하고 있습니다. 아시아태평양, 특히 중국과 일본에서는 정부 이니셔티브와 생명공학 기업과의 제휴를 통해 유전자 편집 연구가 가속화되고 있습니다. 임상시험과 규제 개혁에 대한 중국의 적극적인 참여는 경쟁 구도를 형성하는 데 도움이 되고 있습니다. 라틴아메리카와 중동 및 아프리카는 역량 구축과 미래 유전자 치료 통합을 위한 규제 모델 적용에 중점을 두면서 학술 제휴 및 파일럿 프로그램을 통해 점차 이 분야에 진입하고 있습니다.

유전자 편집 치료제 시장 : 경쟁 상황

유전자교정 치료제 시장의 경쟁 구도는 생명공학 기업, 제약 기업, 안전하고 효과적인 유전자교정 치료제 개발을 위해 노력하는 학술 연구기관이 혼재되어 형성되어 있습니다. 주요 기업들은 CRISPR, TALEN, 징크 핑거 뉴클레아제(ZFN) 기반 치료제를 적극적으로 개발하고 있으며, 다양한 유전성 질환과 만성질환을 타겟으로 하고 있습니다. 바이오테크 스타트업과 대형 제약회사와의 제휴는 임상개발과 승인을 앞당기기 위한 목적으로 점점 더 보편화되고 있습니다. 주목할 만한 진전으로는 혈액 질환에 대한 CRISPR 기반 치료법과 암에 대한 CAR-T 세포 공학 공동 개발 제휴 등이 있습니다. 학술 기관도 중요한 역할을 담당하고 있으며, 초기 단계의 연구와 도구의 개선에 기여하고 나중에 치료용으로 라이센스를 부여하는 데 기여하고 있습니다. 독점 라이선스 계약, 국제 시장 진출, GMP 준수 제조 시설에 대한 투자와 같은 전략적 이니셔티브는 맞춤형 치료와 근본적인 치료법 개발에 중점을 두고 경쟁 우위를 확보하는 데 있어 핵심적인 역할을 하고 있습니다.

북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제13장 주요 벤더 분석 : 유전자 편집 치료제 업계

경쟁 대시보드
기업 개요
- ArsenalBio
- Beam Therapeutics
- Caribou Biosciences
- CRISPR Therapeutics
- Editas Medicine
- EditForce
- Excision BioTherapeutics
- Graphite Bio
- Homology Medicines
- Intellia Therapeutics
- LogicBio Therapeutics
- Poseida Therapeutics
- Precision BioSciences
- Recombinetics
- Sangamo Therapeutics
- Verve Therapeutics
- Others

제14장 AnalystView의 전방위적 분석

ksm 25.07.03

REPORT HIGHLIGHT

Gene Editing Therapeutics Market size was valued at US$ 11.13 Million in 2024, expanding at a CAGR of 147.20% from 2025 to 2032.

The Gene Editing Therapeutics Market centers on the development and commercialization of treatments that correct or modify genetic mutations at the DNA level to treat or potentially cure diseases. With increasing approvals for gene-editing therapies in rare and inherited disorders, the market is expanding into oncology and infectious diseases. In 2023, the U.S. FDA approved the first CRISPR-based therapy for sickle cell anemia, marking a major milestone in clinical gene editing. Technological innovations like base editing and prime editing are enhancing precision while minimizing off-target effects, making gene-editing tools safer for therapeutic use. However, high treatment costs, ethical concerns, and complex regulatory pathways continue to pose significant challenges to widespread adoption. Opportunities exist in the development of personalized medicine, targeting previously untreatable conditions, and expanding gene editing to common diseases, supported by increasing research funding from national health agencies and global biotech collaborations.

Gene Editing Therapeutics Market- Market Dynamics

Breakthrough clinical approvals and precision tools to boost therapeutic adoption

Breakthrough clinical approvals and precision tools are significantly boosting the adoption of gene editing therapeutics worldwide. The U.S. FDA's 2023 approval of the first CRISPR-based therapy for sickle cell disease, developed in partnership with Vertex Pharmaceuticals and CRISPR Therapeutics, marked a historic shift toward clinical application of gene editing. Simultaneously, the National Institutes of Health (NIH) has increased funding for precision genome engineering research, promoting tools like base editing and prime editing to correct mutations with fewer off-target effects. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has initiated accelerated review pathways for gene-editing therapies, aiming to bring advanced treatments to patients faster. These developments reflect a growing global emphasis on safe, efficient, and scalable therapeutic applications of gene editing, reinforcing its potential to transform the treatment of inherited disorders, cancers, and complex diseases.

Gene Editing Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 147.20% over the forecast period (2025-2032)

Based on Technology segmentation, CRISPR was predicted to show maximum market share in the year 2024

Based on Development Stage segmentation, Preclinical was the leading Development Stage in 2024

Based on Therapy Type segmentation, Ex Vivo Gene Editing was the leading Therapy Type in 2024

Based on Disease Indication segmentation, Genetic Disorders were the leading Disease Indication in 2024

Based on end user segmentation, Biopharma Companies was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Gene Editing Therapeutics Market- Segmentation Analysis:

The Global Gene Editing Therapeutics Market is segmented on the basis of Technology, Development Stage, Therapy Type, Disease Indication, End User, and Region.

The market is divided into five categories based on Technology: CRISPR, ZFN, TALEN, Base Editing, and RNA Editing. CRISPR leads due to its simplicity and high efficiency; ZFN offers specificity but requires complex design; TALEN is valued for targeting precision in gene knockout studies; base editing enables single-nucleotide changes; RNA editing allows transient modifications without altering DNA.

The market is divided into five categories based on Development Stage: Preclinical, Phase I, Phase II, Phase III, and Approved. Preclinical dominates with numerous candidates under investigation; Phase I focuses on safety profiling; Phase II explores therapeutic efficacy; Phase III involves large-scale validation across populations; Approved therapies mark successful transition from research to regulated treatment, gaining traction in rare genetic disorders.

Gene Editing Therapeutics Market- Geographical Insights

The Gene Editing Therapeutics Market exhibits strong regional dynamics, with North America at the forefront due to advanced biotech infrastructure, extensive clinical research activity, and supportive regulatory frameworks from agencies like the FDA. The U.S. leads in approvals and trials for CRISPR-based therapies, reinforced by substantial public and private funding. Europe follows closely, where countries such as the UK, Germany, and Switzerland are actively investing in precision medicine, and regulatory bodies like the EMA are increasingly receptive to innovative genetic treatments. The Asia-Pacific region is gaining traction, particularly in China and Japan, where government initiatives and biotech collaborations are accelerating gene editing research. China's active involvement in clinical trials and regulatory reforms is helping shape a competitive landscape. Latin America and the Middle East & and Africa are gradually entering the space through academic partnerships and pilot programs, focusing on capacity building and adapting regulatory models for future gene therapy integration.

Gene Editing Therapeutics Market- Competitive Landscape:

The competitive landscape of the Gene Editing Therapeutics Market is shaped by a mix of biotechnology firms, pharmaceutical companies, and academic research institutions striving to advance safe and effective gene-editing therapies. Leading players are actively developing CRISPR, TALEN, and zinc finger nuclease (ZFN)-based treatments, targeting a wide range of genetic and chronic diseases. Collaborations between biotech startups and large pharmaceutical companies are increasingly common, aimed at accelerating clinical development and regulatory approval. Notable advancements include partnerships to co-develop CRISPR-based therapies for blood disorders and CAR-T cell engineering for cancer. Academic institutions also play a vital role, contributing to early-stage research and tool refinement, which are later licensed for therapeutic use. Strategic initiatives such as exclusive licensing agreements, expansion into international markets, and investment in GMP-compliant manufacturing facilities are becoming central to gaining a competitive advantage, with a strong focus on developing personalized and curative therapies.

Recent Developments:

In May 2025, CRISPR Therapeutics and Sirius Therapeutics have announced a multi-target collaboration to develop novel siRNA therapies, including SRSD107 for thromboembolic disorders, aiming for best-in-class, long-acting gene-based treatments with infrequent dosing and improved patient outcomes.

In May 2025, NIH-supported researchers delivered the first personalized CRISPR gene-editing therapy to an infant with CPS1 deficiency. Using a rapid, customizable platform, the treatment corrected the genetic defect in liver cells within six months, marking a breakthrough for rare disease therapeutics.

In November 2023, Vertex and CRISPR Therapeutics received authorization for the world's first CRISPR-based gene editing therapy for sickle cell disease and beta thalassemia, marking a historic milestone in gene editing therapeutics and offering new hope for patients with these genetic disorders.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GENE EDITING THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

ArsenalBio
Beam Therapeutics
Caribou Biosciences
CRISPR Therapeutics
Editas Medicine
EditForce
Excision BioTherapeutics
Graphite Bio
Homology Medicines
Intellia Therapeutics
LogicBio Therapeutics
Poseida Therapeutics
Precision BioSciences
Recombinetics
Sangamo Therapeutics
Verve Therapeutics
Others

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

CRISPR
ZFN
TALEN
Base Editing
RNA Editing

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DEVELOPMENT STAGE- MARKET ANALYSIS, 2019 - 2032

Preclinical
Phase I
Phase II
Phase III
Approved

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

In Vivo Gene Editing
Ex Vivo Gene Editing

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032

Hematologic Disorders
Genetic Disorders (e.g., Sickle Cell, DMD)
Cancer
Infectious Diseases
Eye Disorders

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Specialty Clinics
Research Organizations
Biopharma Companies

GLOBAL GENE EDITING THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Gene Editing Therapeutics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Gene Editing Therapeutics Market Snippet by Technology
- 2.1.2. Gene Editing Therapeutics Market Snippet by Development Stage
- 2.1.3. Gene Editing Therapeutics Market Snippet by Therapy Type
- 2.1.4. Gene Editing Therapeutics Market Snippet by Disease Indication
- 2.1.5. Gene Editing Therapeutics Market Snippet by End User
- 2.1.6. Gene Editing Therapeutics Market Snippet by Country
- 2.1.7. Gene Editing Therapeutics Market Snippet by Region
2.2. Competitive Insights

3. Gene Editing Therapeutics Key Market Trends

3.1. Gene Editing Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Gene Editing Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Gene Editing Therapeutics Market Opportunities
3.4. Gene Editing Therapeutics Market Future Trends

4. Gene Editing Therapeutics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Gene Editing Therapeutics Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Gene Editing Therapeutics Market Landscape

6.1. Gene Editing Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Gene Editing Therapeutics Market - By Technology

7.1. Overview
- 7.1.1. Segment Share Analysis, By Technology, 2024 & 2032 (%)
- 7.1.2. CRISPR
- 7.1.3. ZFN
- 7.1.4. TALEN
- 7.1.5. Base Editing
- 7.1.6. RNA Editing

8. Gene Editing Therapeutics Market - By Development Stage

8.1. Overview
- 8.1.1. Segment Share Analysis, By Development Stage, 2024 & 2032 (%)
- 8.1.2. Preclinical
- 8.1.3. Phase I
- 8.1.4. Phase II
- 8.1.5. Phase III
- 8.1.6. Approved

9. Gene Editing Therapeutics Market - By Therapy Type

9.1. Overview
- 9.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
- 9.1.2. In Vivo Gene Editing
- 9.1.3. Ex Vivo Gene Editing

10. Gene Editing Therapeutics Market - By Disease Indication

10.1. Overview
- 10.1.1. Segment Share Analysis, By Disease Indication, 2024 & 2032 (%)
- 10.1.2. Hematologic Disorders
- 10.1.3. Genetic Disorders (e.g., Sickle Cell, DMD)
- 10.1.4. Cancer
- 10.1.5. Infectious Diseases
- 10.1.6. Eye Disorders

11. Gene Editing Therapeutics Market - By End User

11.1. Overview
- 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
- 11.1.2. Hospitals
- 11.1.3. Specialty Clinics
- 11.1.4. Research Organizations
- 11.1.5. Biopharma Companies

12. Gene Editing Therapeutics Market- By Geography

12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
- 12.2.1. Overview
- 12.2.2. Gene Editing Therapeutics Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
  - 12.2.9.1. Overview
  - 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.9.3. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.2.9.4. U.S. Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.2.9.5. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.2.9.6. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
  - 12.2.10.1. Overview
  - 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.2.10.3. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.2.10.4. Canada Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.2.10.5. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.2.10.6. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
- 12.3.1. Overview
- 12.3.2. Gene Editing Therapeutics Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
  - 12.3.9.1. Overview
  - 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.9.3. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.3.9.4. Germany Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.3.9.5. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.3.9.6. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.10. UK
  - 12.3.10.1. Overview
  - 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.10.3. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.3.10.4. UK Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.3.10.5. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.3.10.6. UK Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.11. France
  - 12.3.11.1. Overview
  - 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.11.3. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.3.11.4. France Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.3.11.5. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.3.11.6. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.12. Italy
  - 12.3.12.1. Overview
  - 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.12.3. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.3.12.4. Italy Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.3.12.5. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.3.12.6. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.13. Spain
  - 12.3.13.1. Overview
  - 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.13.3. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.3.13.4. Spain Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.3.13.5. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.3.13.6. Spain Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.14. The Netherlands
  - 12.3.14.1. Overview
  - 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.14.3. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.3.14.4. The Netherlands Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.3.14.5. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.3.14.6. The Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
  - 12.3.15.1. Overview
  - 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.15.3. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.3.15.4. Sweden Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.3.15.5. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.3.15.6. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.16. Russia
  - 12.3.16.1. Overview
  - 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.16.3. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.3.16.4. Russia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.3.16.5. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.3.16.6. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.17. Poland
  - 12.3.17.1. Overview
  - 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.17.3. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.3.17.4. Poland Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.3.17.5. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.3.17.6. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.18. Rest of Europe
  - 12.3.18.1. Overview
  - 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.3.18.3. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.3.18.4. Rest of the Europe Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.3.18.5. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.3.18.6. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Gene Editing Therapeutics Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.9. China
  - 12.4.9.1. Overview
  - 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.9.3. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.4.9.4. China Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.4.9.5. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.4.9.6. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.10. India
  - 12.4.10.1. Overview
  - 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.10.3. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.4.10.4. India Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.4.10.5. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.4.10.6. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
  - 12.4.11.1. Overview
  - 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.11.3. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.4.11.4. Japan Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.4.11.5. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.4.11.6. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
  - 12.4.12.1. Overview
  - 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.12.3. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.4.12.4. South Korea Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.4.12.5. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.4.12.6. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
  - 12.4.13.1. Overview
  - 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.13.3. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.4.13.4. Australia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.4.13.5. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.4.13.6. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.14. Indonesia
  - 12.4.14.1. Overview
  - 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.14.3. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.4.14.4. Indonesia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.4.14.5. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.4.14.6. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.15. Thailand
  - 12.4.15.1. Overview
  - 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.15.3. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.4.15.4. Thailand Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.4.15.5. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.4.15.6. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
  - 12.4.16.1. Overview
  - 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.16.3. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.4.16.4. Philippines Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.4.16.5. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.4.16.6. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
  - 12.4.17.1. Overview
  - 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.4.17.3. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.4.17.4. Rest of APAC Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.4.17.5. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Gene Editing Therapeutics Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
  - 12.5.9.1. Overview
  - 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.9.3. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.5.9.4. Brazil Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.5.9.5. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.5.9.6. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
  - 12.5.10.1. Overview
  - 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.10.3. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.5.10.4. Mexico Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.5.10.5. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.5.10.6. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
  - 12.5.11.1. Overview
  - 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.11.3. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.5.11.4. Argentina Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.5.11.5. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.5.11.6. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
  - 12.5.12.1. Overview
  - 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.12.3. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.5.12.4. Colombia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.5.12.5. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.5.12.6. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
  - 12.5.13.1. Overview
  - 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.5.13.3. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.5.13.4. Rest of LATAM Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Gene Editing Therapeutics Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
  - 12.6.9.1. Overview
  - 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.9.3. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.6.9.4. Saudi Arabia Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
  - 12.6.10.1. Overview
  - 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.10.3. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.6.10.4. United Arab Emirates Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
  - 12.6.11.1. Overview
  - 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.11.3. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.6.11.4. Israel Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.6.11.5. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.6.11.6. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
  - 12.6.12.1. Overview
  - 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.12.3. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.6.12.4. Turkey Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.6.12.5. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.6.12.6. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
  - 12.6.13.1. Overview
  - 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.13.3. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.6.13.4. Algeria Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.6.13.5. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.6.13.6. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
  - 12.6.14.1. Overview
  - 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.14.3. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.6.14.4. Egypt Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.6.14.5. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.6.14.6. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
  - 12.6.15.1. Overview
  - 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 12.6.15.3. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  - 12.6.15.4. Rest of MEA Market Size and Forecast, By Development Stage, 2019 - 2032 (US$ Million)
  - 12.6.15.5. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
  - 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
  - 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Gene Editing Therapeutics Industry

13.1. Competitive Dashboard
- 13.1.1. Competitive Benchmarking
- 13.1.2. Competitive Positioning
13.2. Company Profiles
- 13.2.1. ArsenalBio
- 13.2.2. Beam Therapeutics
- 13.2.3. Caribou Biosciences
- 13.2.4. CRISPR Therapeutics
- 13.2.5. Editas Medicine
- 13.2.6. EditForce
- 13.2.7. Excision BioTherapeutics
- 13.2.8. Graphite Bio
- 13.2.9. Homology Medicines
- 13.2.10. Intellia Therapeutics
- 13.2.11. LogicBio Therapeutics
- 13.2.12. Poseida Therapeutics
- 13.2.13. Precision BioSciences
- 13.2.14. Recombinetics
- 13.2.15. Sangamo Therapeutics
- 13.2.16. Verve Therapeutics
- 13.2.17. Others

14. 360 Degree Analyst View

15. Appendix

15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us